Invictus MD Strategies Corp (OTCMKTS:IVITF) has been one of our closely followed favorites over recent months. The company has been quickly establishing a top-tier network of deals. This is a still a very small player, but the balance sheet is strong and top-line growth is kicking along pretty well. IVITF shares have been consolidating the end-of-year push in a healthy lateral fashion over the past 3 weeks as volume remains strong, suggesting a sturdy chasing bid supporting the stock at current levels.
The latest from the company comes in the form of its recent announcement of the sale of its first 120 kg of dried flower from AB Laboratories Inc. (AB Labs), the licensed production facility under the Access to Cannabis for Medical Purposes Regulations, near Hamilton to Canopy Growth Corporation (TSX:WEED), putting Invictus MD’s license holders on track for achieving 26,000 kg run-rate production capacity for 2018 with net capacity of 22,150 kilograms to Invictus MD.
Invictus MD Strategies Corp (OTCMKTS:IVITF) bills itself ostensibly as a company that targets small and mid-size companies with “proven brands, strong customer focus, and significant growth potential. We direct the strategy towards profitability and growth for each of our portfolio companies.”
Moreover, according to a basic description used by the company on several finance hubs, they assist their portfolio companies with “business process integration and by structuring and deploying proper capital to support sustained growth.”
That said, from what we could find, it appears this is now really a Canadian cannabis producer.
According to company materials tagged to recent press releases, “Invictus MD Strategies Corp. is focused on three main verticals within the burgeoning Canadian cannabis sector: Licensed Producers under the ACMPR including an investment in a fully licensed facility, AB Laboratories Inc. as well as the option to now acquire 100% of Acreage Pharms Ltd.; Fertilizer and Nutrients through Future Harvest Development Ltd.; and Cannabis Data and Delivery, with its wholly owned subsidiary Poda Technologies Ltd.”
Find out when $IVITF stock reaches critical levels. Subscribe to OracleDispatch.com Right Now by entering your Email in the box below.
According to its release, the company also notes that it has signed the definitive agreement to bump up its strategic investment in AB Labs, pushing involvement from its current 33.3 percent ownership interest to 50 percent.
“Patients routinely get in touch with AB Labs inquiring about our high-quality product. Now, they can take advantage of Canopy Growth’s Tweed Main Street to gain immediate and detailed information about our artisan cannabis. The effort gives us immediate access to the largest customer base in the rapidly expanding medical cannabis market,” said Dan Kriznic, Chairman and CEO of Invictus MD. “Our collaboration with Canopy Growth demonstrates our commitment to making the sector strong and helping to expose medical cannabis patients visiting Tweed Main Street, to another high quality, unique brand.”
“On behalf of the Canopy Growth team, I want to congratulate the AB Labs team for achieving this milestone,” said Mark Zekulin, president, Canopy Growth. “AB Labs is now the second CraftGrow partner to successfully transfer cannabis products to be sold through our Tweed Main Street e-commerce platform. We hope to have AB Labs cannabis available to our customers this quarter and look forward to many more successful transfers in the future.”
“The increase in our ownership of AB Labs and the renovations of the Secondary Facility that will provide a combined production space at AB Labs and Acreage Pharms of approximately 95,000 square feet, will dramatically advance our timeline for increasing our expected annual run-rate production capacity at our facilities to 26,000 kg’s in 2018 and 76,000 kg’s in 2019 in time for the adult-use market. Invictus MD’s funded capacity today is approximately 20,600 kg’s making it one of the top licensed producers in Canada” said Dan Kriznic, Chairman and CEO, of Invictus MD. “Increasing our production capacity has been a sharp focus of the Company. Our production will satisfy the significant demand in Canada for high quality, standardized, pesticide free product for the current medical cannabis market and recreational market that is expected to begin mid-2018.”
Currently trading at a market capitalization of $153.9M, IVITF has a significant war chest ($3.1M) of cash on the books, which must be weighed relative to virtually no total current liabilities. IVITF is pulling in trailing 12-month revenues of $1.8M. In addition, the company is seeing major top-line growth, with y/y quarterly revenues growing at 24.7%. As more color becomes clear on the name, we will review the situation and update our take. Sign-up for continuing coverage on shares of $IVITF stock, as well as other hot stock picks, get our free newsletter today and get our next breakout pick!
Disclosure: we hold no position in $IVITF, either long or short, and we have not been compensated for this article.